You are here

Tecfidera

Biogen chalks up a Tecfidera patent win in Europe after losing US protections

Biogen chalks up a Tecfidera patent win in Europe after losing US protections

Fierce Pharma

multiple sclerosis

Flag link:

Biogen gets EU court ruling in favor of blocking Tecfidera generic entry

Biogen gets EU court ruling in favor of blocking Tecfidera generic entry

Seeking Alpha

multiple sclerosis

Flag link:

Biogen gains prominent ally in bid for Supreme Court to review Tecfidera patent case

Biogen gains prominent ally in bid for Supreme Court to review Tecfidera patent case

Fierce Pharma

Flag link:

Split U.S. appeals court rejects Biogen bid to revive MS drug patent dispute

Split U.S. appeals court rejects Biogen bid to revive MS drug patent dispute

Reuters

multiple sclerosis

Flag link:

Biogen takes another blow as appeal for Tecfidera patent revival falls short

Biogen takes another blow as appeal for Tecfidera patent revival falls short

Fierce Pharma

multiple sclerosis

Flag link:

Biogen is running out of safety nets

Biogen is running out of safety nets

BioPharma Dive

Flag link:

Mylan launches first generic to Tecfidera in multiple sclerosis

Mylan launches first generic to Tecfidera in multiple sclerosis

Seeking Alpha

multiple sclerosis

Flag link:

Biogen's last-ditch pitch for an injunction to protect Tecfidera is denied, paving way for Mylan generic

Biogen's last-ditch pitch for an injunction to protect Tecfidera is denied, paving way for Mylan generic

Endpoints

Flag link:

Mylan, looking to capitalize on Biogen's Tecfidera patent loss, faces fork in the road on generic launch

Mylan, looking to capitalize on Biogen's Tecfidera patent loss, faces fork in the road on generic launch

Fierce Pharma

multiple sclerosis

Flag link:

Judge wipes out Biogen's Tecfidera patent protections in suit against Mylan

Judge wipes out Biogen's Tecfidera patent protections in suit against Mylan

Fierce Pharma

multiple sclerosis

Flag link:

Will Biogen’s Big Patent Victory Ease Investor Worries About Its Alzheimer’s Drug?

Will Biogen’s Big Patent Victory Ease Investor Worries About Its Alzheimer’s Drug?

Motley Fool

Alzheimer's disease

multiple sclerosis

Flag link:

Biogen wins Tecfidera patent challenge from Mylan, sending shares way up

Biogen wins Tecfidera patent challenge from Mylan, sending shares way up

Fierce Pharma

multiple sclerosis

Flag link:

Why Biogen's Recent Rebound May Not Last -- at Least for Now

Why Biogen's Recent Rebound May Not Last -- at Least for Now

Motley Fool

multiple sclerois

Alzheimer's disease

Flag link:

Vumerity’s $88,000 List Price Not What ‘We Had Hoped,’ National MS Society Says

Vumerity’s $88,000 List Price Not What ‘We Had Hoped,’ National MS Society Says

Multiple Sclerosis News Today

multiple sclerosis

Flag link:

A new company enters the Tecfidera fight, offering to kill two birds

A new company enters the Tecfidera fight, offering to kill two birds

Endpoints

Vitalis Pharmaceuticals

Flag link:

Biogen, wrestling MS rivals, touts 10 year-plus Tecfidera data

Biogen, wrestling MS rivals, touts 10 year-plus Tecfidera data

Fierce Pharma

multiple sclerosis

Flag link:

Biogen beats estimates on multiple sclerosis therapy sales Reuters

Biogen beats estimates on multiple sclerosis therapy sales Reuters

Yahoo/Reuters

Flag link:

Troubled Biogen shows off its me-better approach to MS on PhIII update — but is it really just a patent play?

Troubled Biogen shows off its me-better approach to MS on PhIII update — but is it really just a patent play?

Endpoints

multiple sclerosis

Flag link:

Upcoming events – key tests approach for Biogen and Kalvista

Upcoming events – key tests approach for Biogen and Kalvista

EP Vantage

multiple sclerosis

Flag link:

After Alzheimer’s collapse, Biogen must win Tecfidera patent challenge

After Alzheimer’s collapse, Biogen must win Tecfidera patent challenge

EP Vantage

Alzheimer's disease

Flag link:

Pages